Other Oncology Formulations

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine is a sterile liquid suspension of virus-like particles (VLPs) of the L1 major capsid protein on the WHO Model List of Essential Medicines. It stimulates high titers of neutralizing IgG antibodies that transudate into cervicovaginal secretions, blocking HPV entry into basal epithelial cells. Types 16 and 18 cause ~70% of cervical cancers, anal cancers, and precancerous lesions (CIN 2/3), while types 6 and 11 cause ~90% of anogenital warts (condyloma acuminata). Indicated for prevention of cervical, vulvar, vaginal, and anal cancers, precancerous dysplasias, and genital warts in females and males aged 9 through 26 (and up to 45 years).